PATIENT PREFERENCE FOR EXTENDED PALLIATIVE CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER

被引：10

作者：

HICKISH, TF

SMITH, IE

MIDDLETON, G

NICOLSON, M

机构：

[1] ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND

[2] ABERDEEN ROYAL INFIRM,ABERDEEN,SCOTLAND

来源：

LANCET | 1995年 / 345卷 / 8953期

关键词：

D O I：

10.1016/S0140-6736(95)92993-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：857 / 858

页数：2

相关论文

共 5 条

[1] IS CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER WORTHWHILE
COATES, A
FORBES, J
[J]. LANCET, 1993, 342 (8862) : 4 - 4
[2] CULLEN MH, LUNG CANCER, V9, pS81
[3] SYMPTOM RELIEF WITH MVP (MITOMYCIN-C, VINBLASTINE AND CISPLATIN) CHEMOTHERAPY IN ADVANCED NON-SMALL-CELL LUNG-CANCER
ELLIS, PA
SMITH, IE
HARDY, JR
NICOLSON, MC
TALBOT, DC
ASHLEY, SE
PRIEST, K
[J]. BRITISH JOURNAL OF CANCER, 1995, 71 (02) : 366 - 370
[4] COUNTING THE COSTS OF CHEMOTHERAPY IN A NATIONAL-CANCER-INSTITUTE-OF-CANADA RANDOMIZED TRIAL IN NONSMALL-CELL LUNG-CANCER
JAAKKIMAINEN, L
GOODWIN, PJ
PATER, J
WARDE, P
MURRAY, N
RAPP, E
[J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (08) : 1301 - 1309
[5] SOUQUET PJ, 1993, LANCET, V342, P19